Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 9;11:583311. doi: 10.3389/fphar.2020.583311

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Grymonprez, Steurbaut, De Backer, Petrovic and Lahousse

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Forest plot of the risk of major bleeding of NOACs versus VKAs in elderly atrial fibrillation patients ≥75 years old. Api 5/2.5, apixaban 5 mg (standard dose) and 2.5 mg (reduced dose); CI, confidence interval; Dabi 150, dabigatran 150 mg (standard dose); Dabi 110, dabigatran 110 mg (reduced dose); Edo 60/30, edoxaban 60 mg (standard dose) and 30 mg (reduced dose); HR, hazard ratio; MB, major bleeding; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized controlled trial (post hoc analysis); RE model, random effects model; Riva, rivaroxaban; Riva 20/15, rivaroxaban 20 mg (standard dose) and 15 mg (reduced dose); Riva 15/10, rivaroxaban 15 mg (standard dose) and 10 mg (reduced dose); VKA, vitamin K antagonist.